AI + Digital Maturity in Contract Manufacturing
Exclusive Report

CDMO Periodic Table

Download

CDMO Live Europe 2026 Early Bird

Agenda Download

Days

Hours

Minutes

Seconds

CDMO News

Scinai Immunotherapeutics Secures $2.61 Million in Private Placement

OneSource Speciality Pharma Supports FDA Tentative Approval for Semaglutide Injection ANDA

Evonik Invests EUR 80 Million to Expand Biotechnology Capacity in Slovakia

WuXi Biologics Completes Structure of 95,000 m² Chengdu Microbial Manufacturing Site

WuXi Biologics Secures MFDS GMP Certification for 3 Wuxi Facilities

Benuvia and Mikart Announce Strategic Co-Marketing Partnership for End-to-End CDMO Services

Plus Therapeutics Initiates Manufacturing and Technology Transfer with SpectronRx for REYOBIQ

Simulations Plus Partners with Lonza and FDA on ASD Drug Modeling Framework

Tempest Therapeutics Achieves Manufacturing Milestone for TPST-2003 CAR-T Therapy

Made Scientific Partners with Regenicin to Manufacture NovaDerm for FDA Orphan Approval Pathway

Samsung Biologics Reports Q1 2026 Revenue of KRW 1,257 Billion($849M) and Profit of KRW 581 Billion($392M)

More CDMO News

OneSource Speciality Pharma Supports FDA Tentative Approval for Semaglutide Injection ANDA

Evonik Invests EUR 80 Million to Expand Biotechnology Capacity in Slovakia

WuXi Biologics Completes Structure of 95,000 m² Chengdu Microbial Manufacturing Site

WuXi Biologics Secures MFDS GMP Certification for 3 Wuxi Facilities

Benuvia and Mikart Announce Strategic Co-Marketing Partnership for End-to-End CDMO Services

Plus Therapeutics Initiates Manufacturing and Technology Transfer with SpectronRx for REYOBIQ

Simulations Plus Partners with Lonza and FDA on ASD Drug Modeling Framework

Tempest Therapeutics Achieves Manufacturing Milestone for TPST-2003 CAR-T Therapy

Made Scientific Partners with Regenicin to Manufacture NovaDerm for FDA Orphan Approval Pathway

Samsung Biologics Reports Q1 2026 Revenue of KRW 1,257 Billion($849M) and Profit of KRW 581 Billion($392M)

More CDMO News

White Paper[Download]

Why Compliance-Driven CDMOs Win Sponsor Contracts

RESOURCES

CDMO News

CDMO News

Scinai Immunotherapeutics Secures $2.61 Million in Private Placement

Scinai Immunotherapeutics Secures $2.61 Million in Private Placement

OneSource Speciality Pharma Supports FDA Tentative Approval for Semaglutide Injection ANDA

Evonik Invests EUR 80 Million to Expand Biotechnology Capacity in Slovakia

WuXi Biologics Completes Structure of 95,000 m² Chengdu Microbial Manufacturing Site

WuXi Biologics Secures MFDS GMP Certification for 3 Wuxi Facilities

Benuvia and Mikart Announce Strategic Co-Marketing Partnership for End-to-End CDMO Services

Plus Therapeutics Initiates Manufacturing and Technology Transfer with SpectronRx for REYOBIQ

Simulations Plus Partners with Lonza and FDA on ASD Drug Modeling Framework

Tempest Therapeutics Achieves Manufacturing Milestone for TPST-2003 CAR-T Therapy

Made Scientific Partners with Regenicin to Manufacture NovaDerm for FDA Orphan Approval Pathway

Samsung Biologics Reports Q1 2026 Revenue of KRW 1,257 Billion($849M) and Profit of KRW 581 Billion($392M)

OneSource Speciality Pharma Supports FDA Tentative Approval for Semaglutide Injection ANDA

Evonik Invests EUR 80 Million to Expand Biotechnology Capacity in Slovakia

WuXi Biologics Completes Structure of 95,000 m² Chengdu Microbial Manufacturing Site

WuXi Biologics Secures MFDS GMP Certification for 3 Wuxi Facilities

Benuvia and Mikart Announce Strategic Co-Marketing Partnership for End-to-End CDMO Services

Plus Therapeutics Initiates Manufacturing and Technology Transfer with SpectronRx for REYOBIQ

Simulations Plus Partners with Lonza and FDA on ASD Drug Modeling Framework

Tempest Therapeutics Achieves Manufacturing Milestone for TPST-2003 CAR-T Therapy

Made Scientific Partners with Regenicin to Manufacture NovaDerm for FDA Orphan Approval Pathway

Samsung Biologics Reports Q1 2026 Revenue of KRW 1,257 Billion($849M) and Profit of KRW 581 Billion($392M)

Why Compliance-Driven CDMOs Win Sponsor Contracts

CDMO Contract Negotiations Timelines Explained

Target Product Profile (TPP) Explained

Drug Development Readiness: Interactive Checklist and RACI

Welcome to PharmaSource

Follow us

Top Links

Get in touch